Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial.
ART outcomes
Astaxanthin
Cell-free DNA
Diminished ovarian reserve
Inflammation
Oxidative stress
Poor ovarian response
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
10
08
2024
accepted:
15
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Poor ovarian response (POR) to controlled ovarian stimulation (COS) remains challenging, especially in advanced-age women with diminished ovarian reserve, resulting in low live birth rates. Many patients prefer to conceive with their eggs, underscoring the need for improved treatments. This study explores astaxanthin potential as a COS adjuvant to improve ovarian response and assisted reproductive technology (ART) outcomes, considering its impact on oxidative stress (OS), inflammation, and apoptosis, which are key factors in POR. In this randomized, triple-blind, placebo-controlled trial, 60 infertile POR patients from POSEIDON Group 4 (the poorest prognosis category, age > 35 and poor ovarian reserve (anti-müllerian hormone < 1.2 ng/ml or antral follicle count < 5) undergoing intracytoplasmic sperm injection were enrolled. Patients were assigned to receive either 12 mg/day AST or placebo for eight weeks. All patients underwent a gonadotropin-releasing hormone antagonist regimen for COS. ART outcomes were compared between groups. Blood serum and follicular fluid (FF) were analyzed for OS markers (superoxide dismutase [SOD], total antioxidant capacity [TAC], and malondialdehyde [MDA]), and pro-inflammatory cytokines (interleukin-6 [IL-6], interleukin-8 [IL-8], and vascular endothelial growth factor [VEGF]) via enzyme-linked immunosorbent assay kits, and cell-free DNA [cfDNA] (apoptotic marker) via ALU quantitative polymerase chain reaction. After the intervention, the AST group exhibited a significant elevation in serum (P = 0.013) and TAC (P = 0.030), accompanied by a significant reduction in serum MDA (P = 0.005). No significant differences between AST and placebo groups were observed in OS markers in FF. AST group showed significant reductions in the serum IL-6 (P < 0.001), IL-8 (P = 0.001), and VEGF (P = 0.002) levels following AST therapy. In the AST group, FF levels of IL-6 (P = 0 < 001), IL-8 (P = 0.036), VEGF (P = 0.006), and cfDNA (P < 0.001) were significantly lower than in the placebo group. Between-group comparisons showed significant differences in the alterations of serum SOD (P = 0.027), IL-6 (P < 0.001), and IL-8 (P = 0.035) levels between AST and placebo groups. The AST group showed significant increases in the number of retrieved oocytes (P = 0.003), MII oocytes (P = 0.004), frozen embryos (P = 0.037), and high-quality embryos (P = 0.014) compared to the placebo group. AST shows promise as a COS adjuvant therapy, potentially enhancing some ART outcomes in POR through alleviating OS, inflammation, and apoptosis. Clinical trial registration number: IRCT20230223057510N1, URL: https://irct.behdasht.gov.ir/trial/68870 , registration date: 2023 March 16.
Sections du résumé
BACKGROUND
BACKGROUND
Poor ovarian response (POR) to controlled ovarian stimulation (COS) remains challenging, especially in advanced-age women with diminished ovarian reserve, resulting in low live birth rates. Many patients prefer to conceive with their eggs, underscoring the need for improved treatments. This study explores astaxanthin potential as a COS adjuvant to improve ovarian response and assisted reproductive technology (ART) outcomes, considering its impact on oxidative stress (OS), inflammation, and apoptosis, which are key factors in POR.
METHODS
METHODS
In this randomized, triple-blind, placebo-controlled trial, 60 infertile POR patients from POSEIDON Group 4 (the poorest prognosis category, age > 35 and poor ovarian reserve (anti-müllerian hormone < 1.2 ng/ml or antral follicle count < 5) undergoing intracytoplasmic sperm injection were enrolled. Patients were assigned to receive either 12 mg/day AST or placebo for eight weeks. All patients underwent a gonadotropin-releasing hormone antagonist regimen for COS. ART outcomes were compared between groups. Blood serum and follicular fluid (FF) were analyzed for OS markers (superoxide dismutase [SOD], total antioxidant capacity [TAC], and malondialdehyde [MDA]), and pro-inflammatory cytokines (interleukin-6 [IL-6], interleukin-8 [IL-8], and vascular endothelial growth factor [VEGF]) via enzyme-linked immunosorbent assay kits, and cell-free DNA [cfDNA] (apoptotic marker) via ALU quantitative polymerase chain reaction.
RESULTS
RESULTS
After the intervention, the AST group exhibited a significant elevation in serum (P = 0.013) and TAC (P = 0.030), accompanied by a significant reduction in serum MDA (P = 0.005). No significant differences between AST and placebo groups were observed in OS markers in FF. AST group showed significant reductions in the serum IL-6 (P < 0.001), IL-8 (P = 0.001), and VEGF (P = 0.002) levels following AST therapy. In the AST group, FF levels of IL-6 (P = 0 < 001), IL-8 (P = 0.036), VEGF (P = 0.006), and cfDNA (P < 0.001) were significantly lower than in the placebo group. Between-group comparisons showed significant differences in the alterations of serum SOD (P = 0.027), IL-6 (P < 0.001), and IL-8 (P = 0.035) levels between AST and placebo groups. The AST group showed significant increases in the number of retrieved oocytes (P = 0.003), MII oocytes (P = 0.004), frozen embryos (P = 0.037), and high-quality embryos (P = 0.014) compared to the placebo group.
CONCLUSION
CONCLUSIONS
AST shows promise as a COS adjuvant therapy, potentially enhancing some ART outcomes in POR through alleviating OS, inflammation, and apoptosis.
TRIAL REGISTRATION
BACKGROUND
Clinical trial registration number: IRCT20230223057510N1, URL: https://irct.behdasht.gov.ir/trial/68870 , registration date: 2023 March 16.
Identifiants
pubmed: 39482765
doi: 10.1186/s13048-024-01537-7
pii: 10.1186/s13048-024-01537-7
doi:
Substances chimiques
astaxanthine
8XPW32PR7I
Xanthophylls
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Subventions
Organisme : Tehran University of Medical Sciences, Tehran, Iran
ID : 1401-4-410-64220
Informations de copyright
© 2024. The Author(s).
Références
Giannelou P, Simopoulou M, Grigoriadis S, Makrakis E, Kontogeorgi A, Pantou A, et al. The conundrum of poor ovarian response: from diagnosis to treatment. Diagnostics (Basel). 2020;10(9):687.
pubmed: 32932955
doi: 10.3390/diagnostics10090687
Venetis CA, Kolibianakis EM, Tarlatzi TB, Tarlatzis BC. Evidence-based management of poor ovarian response. Ann N Y Acad Sci. 2010;1205(1):199–206.
pubmed: 20840273
doi: 10.1111/j.1749-6632.2010.05665.x
Drakopoulos P, Blockeel C, Stoop D, Camus M, De Vos M, Tournaye H, Polyzos NP. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31(2):370–6.
pubmed: 26724797
Law YJ, Zhang N, Kolibianakis EM, Costello MF, Keller E, Chambers GM, Venetis CA. Is there an optimal number of oocytes retrieved at which live birth rates or cumulative live birth rates per aspiration are maximized after ART? A systematic review. Reprod Biomed Online. 2021;42(1):83–104.
pubmed: 33390313
doi: 10.1016/j.rbmo.2020.10.008
Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, Definition EPOR. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–24.
pubmed: 21505041
doi: 10.1093/humrep/der092
Alviggi C, Andersen C, Buehler K, Conforti A, De Placido G, Esteves S, et al. Poseidon Group (patient-Oriented strategies encompassing IndividualizeD oocyte number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452–3.
pubmed: 26921622
doi: 10.1016/j.fertnstert.2016.02.005
Annalisa R, Dominic S, Nikolaos PP. Diminished ovarian reserve and poor ovarian response: diagnostic and therapeutic management. Front Physiol. 2022;13:827678.
Nunez-Calonge R, Cortes S, Gutierrez Gonzalez LM, Kireev R, Vara E, Ortega L, et al. Oxidative stress in follicular fluid of young women with low response compared with fertile oocyte donors. Reprod Biomed Online. 2016;32(4):446–56.
pubmed: 26805046
doi: 10.1016/j.rbmo.2015.12.010
Taghavi SA, Ashrafi M, Mehdizadeh M, Karimian L, Joghataie MT, Aflatoonian R. Toll-like receptors expression in follicular cells of patients with poor ovarian response. Int J Fertil Steril. 2014;8(2):183–92.
pubmed: 25083184
Luddi A, Capaldo A, Focarelli R, Gori M, Morgante G, Piomboni P, De Leo V. Antioxidants reduce oxidative stress in follicular fluid of aged women undergoing IVF. Reprod Biol Endocrinol. 2016;14(1):57.
pubmed: 27604261
doi: 10.1186/s12958-016-0184-7
Regan SLP, Knight PG, Yovich JL, Leung Y, Arfuso F, Dharmarajan A. Granulosa Cell apoptosis in the ovarian Follicle-A changing view. Front Endocrinol (Lausanne). 2018;9:61.
pubmed: 29551992
doi: 10.3389/fendo.2018.00061
Kaltsas A, Zikopoulos A, Moustakli E, Zachariou A, Tsirka G, Tsiampali C, et al. The Silent threat to women’s fertility: uncovering the devastating effects of oxidative stress. Antioxid (Basel). 2023;12(8):1490.
doi: 10.3390/antiox12081490
Adashi EY. Endocrinology of the ovary. Hum Reprod. 1994;9(5):815–27.
pubmed: 7929728
doi: 10.1093/oxfordjournals.humrep.a138602
Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta Mol Cell Res. 2016;1863(12):2977–92.
doi: 10.1016/j.bbamcr.2016.09.012
Yan F, Zhao Q, Li Y, Zheng Z, Kong X, Shu C, et al. The role of oxidative stress in ovarian aging: a review. J Ovarian Res. 2022;15(1):100.
pubmed: 36050696
doi: 10.1186/s13048-022-01032-x
Regan S, Knight P, Yovich J, Leung Y, Arfuso F, Dharmarajan A. Granulosa cell apoptosis in the ovarian follicle-a changing view. Front Endocrinol. 2018;9(2018):61.
doi: 10.3389/fendo.2018.00061
Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci. 2014;51(4):200–31.
pubmed: 24878357
doi: 10.3109/10408363.2014.914888
Scalici E, Traver S, Molinari N, Mullet T, Monforte M, Vintejoux E, Hamamah S. Cell-free DNA in human follicular fluid as a biomarker of embryo quality. Hum Reprod. 2014;29(12):2661–9.
pubmed: 25267787
doi: 10.1093/humrep/deu238
Traver S, Assou S, Scalici E, Haouzi D, Al-Edani T, Belloc S, Hamamah S. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy. Hum Reprod Update. 2014;20(6):905–23.
pubmed: 24973359
doi: 10.1093/humupd/dmu031
Baka S, Malamitsi-Puchner A. Novel follicular fluid factors influencing oocyte developmental potential in IVF: a review. Reprod Biomed Online. 2006;12(4):500–6.
pubmed: 16740225
doi: 10.1016/S1472-6483(10)62005-6
Ficicioglu C, Cenksoy PO, Yildirim G, Kaspar C. Which cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis. Gynecol Endocrinol. 2014;30(5):372–6.
pubmed: 24576292
doi: 10.3109/09513590.2014.887064
Seifer DB, Gardiner AC, Ferreira KA, Peluso JJ. Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization. Fertil Steril. 1996;66(4):593–8.
pubmed: 8816622
doi: 10.1016/S0015-0282(16)58573-2
Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: a systematic review and meta-analysis. J Hum Reprod Sci. 2016;9(2):70–81.
pubmed: 27382230
pmcid: 4915289
doi: 10.4103/0974-1208.183515
Blumenfeld Z. What is the best regimen for ovarian stimulation of poor responders in ART/IVF? Front Endocrinol (Lausanne). 2020;11:192.
pubmed: 32362870
doi: 10.3389/fendo.2020.00192
Gong Y, Luo S, Fan P, Jin S, Zhu H, Deng T, et al. Growth hormone alleviates oxidative stress and improves oocyte quality in Chinese women with polycystic ovary syndrome: a randomized controlled trial. Sci Rep. 2020;10(1):18769.
pubmed: 33127971
pmcid: 7599233
doi: 10.1038/s41598-020-75107-4
Xu Y, Nisenblat V, Lu C, Li R, Qiao J, Zhen X, Wang S. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reprod Biol Endocrinol. 2018;16(1):29.
pubmed: 29587861
pmcid: 5870379
doi: 10.1186/s12958-018-0343-0
Wang J, Liu B, Wen J, Qu B. The role of dehydroepiandrosterone in improving in vitro fertilization outcome in patients with DOR/POR: a systematic review and Meta- analysis. Comb Chem High Throughput Screen. 2023;26(5):916–27.
pubmed: 35996249
doi: 10.2174/1386207325666220820164357
Kohandel Z, Farkhondeh T, Aschner M, Samarghandian S. Nrf2 a molecular therapeutic target for Astaxanthin. Biomed Pharmacother. 2021;137:111374.
pubmed: 33761600
doi: 10.1016/j.biopha.2021.111374
Ambati RR, Phang SM, Ravi S, Aswathanarayana RG. Astaxanthin: sources, extraction, stability, biological activities and its commercial applications–a review. Mar Drugs. 2014;12(1):128–52.
pubmed: 24402174
pmcid: 3917265
doi: 10.3390/md12010128
Suyono EA, Pradani L, Mu’avatun U, Habiba RN, Rohma EF. Combination of blue, red, white, and ultraviolet lights for increasing carotenoids and biomass of microalga Haematococcus pluvialis. Procedia Environ Sci. 2015;28:399–405.
doi: 10.1016/j.proenv.2015.07.049
Howden R. Nrf2 and cardiovascular defense. Oxid Med Cell Longev. 2013;2013(1):104308.
Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea F. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006;46(2):185–96.
pubmed: 16431409
doi: 10.1080/10408690590957188
Kohandel Z, Farkhondeh T, Aschner M, Pourbagher-Shahri AM, Samarghandian S. Anti-inflammatory action of astaxanthin and its use in the treatment of various diseases. Biomed Pharmacother. 2022;145: 112179.
pubmed: 34736076
doi: 10.1016/j.biopha.2021.112179
Zhang H, Tsao R. Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects. Curr Opin Food Sci. 2016;8:33–42.
doi: 10.1016/j.cofs.2016.02.002
Kim SH, Kim H. Astaxanthin modulation of signaling pathways that regulate autophagy. Mar Drugs. 2019;17(10): 546.
pubmed: 31547619
pmcid: 6836186
doi: 10.3390/md17100546
Yan T, Zhao Y, Zhang X, Lin X. Astaxanthin inhibits acetaldehyde-induced cytotoxicity in SH-SY5Y cells by modulating Akt/CREB and p38MAPK/ERK signaling pathways. Mar Drugs. 2016;14(3): 56.
pubmed: 26978376
pmcid: 4820310
doi: 10.3390/md14030056
Jabarpour M, Aleyasin A, Nashtaei MS, Lotfi S, Amidi F. Astaxanthin treatment ameliorates ER stress in polycystic ovary syndrome patients: a randomized clinical trial. Sci Rep. 2023;13(1):3376.
pubmed: 36854788
pmcid: 9974957
doi: 10.1038/s41598-023-28956-8
Brendler T, Williamson EM. Astaxanthin: how much is too much? A safety review. Phytother Res. 2019;33(12):3090–111.
pubmed: 31788888
doi: 10.1002/ptr.6514
Williamson EM, Liu X, Izzo AA. Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals. Br J Pharmacol. 2020;177(6):1227–40.
pubmed: 31799702
pmcid: 7056462
doi: 10.1111/bph.14943
Maleki-Hajiagha A, Shafie A, Maajani K, Amidi F. Effect of astaxanthin supplementation on female fertility and reproductive outcomes: a systematic review and meta-analysis of clinical and animal studies. J Ovarian Res. 2024;17(1):163.
pubmed: 39127677
doi: 10.1186/s13048-024-01472-7
Rostami S, Alyasin A, Saedi M, Nekoonam S, Khodarahmian M, Moeini A, Amidi F. Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: a randomized, triple-blind placebo-controlled clinical trial. Front Endocrinol (Lausanne). 2023;14:1144323.
pubmed: 37020589
doi: 10.3389/fendo.2023.1144323
Gharaei R, Alyasin A, Mahdavinezhad F, Samadian E, Ashrafnezhad Z, Amidi F. Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome. J Assist Reprod Genet. 2022;39(4):995–1008.
pubmed: 35237893
doi: 10.1007/s10815-022-02432-0
Fereidouni F, Kashani L, Amidi F, Khodarahmian M, Zhaeentan S, Ardehjani NA, Rastegar T. Astaxanthin treatment decreases pro-inflammatory cytokines and improves reproductive outcomes in patients with polycystic ovary syndrome undergoing assisted reproductive technology: a randomized clinical trial. Inflammopharmacology. 2024;32(4):2337–47.
pubmed: 38916710
doi: 10.1007/s10787-024-01504-0
Jabarpour M, Aleyasin A, Nashtaei MS, Khodarahmian M, Lotfi S, Amidi F. The modulating effects of astaxanthin on apoptosis in women with polycystic ovarian syndrome: a randomized clinical trial. Avicenna J Phytomed. 2024;14(1):64–77.
pubmed: 38948179
Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047.
pubmed: 26539470
doi: 10.1155/2015/217047
Traver S, Scalici E, Mullet T, Molinari N, Vincens C, Anahory T, Hamamah S. Cell-free DNA in human follicular microenvironment: New Prognostic Biomarker to predict in vitro fertilization outcomes. PLoS ONE. 2015;10(8): e0136172.
pubmed: 26288130
doi: 10.1371/journal.pone.0136172
Debbarh H, Jamil M, Jelloul H, Zakaria A, Louanjli N, Cadi R. Assessment of cell-free DNA and apoptosis in an oocyte microenvironment: promising biomarkers to predict intracytoplasmic sperm injection outcomes. Zygote. 2023;31(3):296–302.
pubmed: 37066898
doi: 10.1017/S0967199423000126
Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52(6):1062–9.
pubmed: 16723681
doi: 10.1373/clinchem.2006.068577
Group ECPW, Vlaisavljevic V, Apter S, Capalbo A, D’Angelo A, Gianaroli L, et al. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open. 2021;2021(3):hoab022.
doi: 10.1093/hropen/hoab022
of Embryology ESIG. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Reprod Biomed Online. 2017;35(5):494–510.
doi: 10.1016/j.rbmo.2017.06.015
Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011;26(6):1270–83.
Bassiouny YA, Dakhly DMR, Bayoumi YA, Hashish NM. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril. 2016;105(3):697–702.
pubmed: 26690008
doi: 10.1016/j.fertnstert.2015.11.026
Safdarian L, Aghahosseini M, Alyasin A, Samaei-Nouroozi A, Rashidi S, Shabani-Nashtaei M, et al. Growth hormone (GH) improvement of ovarian responses and pregnancy outcome in poor ovarian responders: a randomized study. Asian Pac J Cancer Prev. 2019;20(7):2033.
pubmed: 31350962
pmcid: 6745232
doi: 10.31557/APJCP.2019.20.7.2033
Mohammadi S, Eini F, Bazarganipour F, Taghavi SA, Kutenaee MA. The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial. Reprod Biol Endocrinol. 2021;19:1–7.
doi: 10.1186/s12958-021-00741-0
Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria—the why. Front Endocrinol (Lausanne). 2018;9:461.
pubmed: 30174650
doi: 10.3389/fendo.2018.00461
Abu-Musa A, Haahr T, Humaidan P. Novel physiology and definition of poor ovarian response; clinical recommendations. Int J Mol Sci. 2020;21(6): 2110.
pubmed: 32204404
doi: 10.3390/ijms21062110
Kaltsas A, Zikopoulos A, Moustakli E, Zachariou A, Tsirka G, Tsiampali C, et al. The Silent threat to women’s fertility: uncovering the devastating effects of oxidative stress. Antioxidants. 2023;12(8): 1490.
pubmed: 37627485
doi: 10.3390/antiox12081490
Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol. 2012;10: 49.
pubmed: 22748101
doi: 10.1186/1477-7827-10-49
Rasool S, Shah D. Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel’s back. Fertil Res Pract. 2017;3(1):15.
pubmed: 29046817
doi: 10.1186/s40738-017-0041-1
Jiménez Tuñón JM, Trilles PP, Molina MG, Duvison MH, Pastor BM, Martín PS, et al. A double-blind, randomized prospective study to evaluate the efficacy of previous therapy with melatonin, myo-inositol, folic acid, and selenium in improving the results of an assisted reproductive treatment. Clin Med Insights Ther. 2017;9:1179559X17742902.
doi: 10.1177/1179559X17742902
Choi HD, Youn YK, Shin WG. Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects. Plant Foods Hum Nutr. 2011;66:363–9.
pubmed: 21964877
doi: 10.1007/s11130-011-0258-9
Choi HD, Kim JH, Chang MJ, Kyu-Youn Y, Shin WG. Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother Res. 2011;25(12):1813–8.
pubmed: 21480416
doi: 10.1002/ptr.3494
Akhter N, Wilson A, Thomas R, Al-Rashed F, Kochumon S, Al-Roub A, et al. ROS/TNF-alpha crosstalk triggers the expression of IL-8 and MCP-1 in human monocytic THP-1 cells via the NF-kappaB and ERK1/2 mediated signaling. Int J Mol Sci. 2021;22(19):10519.
pubmed: 34638857
doi: 10.3390/ijms221910519
Schäfer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Höcker M. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1-and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem. 2003;278(10):8190–8.
pubmed: 12509426
doi: 10.1074/jbc.M211999200
Talukdar J, Bhadra B, Dattaroy T, Nagle V, Dasgupta S. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19. Biomed Pharmacother. 2020;132: 110886.
pubmed: 33113418
pmcid: 7566765
doi: 10.1016/j.biopha.2020.110886
Chang MX, Xiong F. Astaxanthin and its effects in inflammatory responses and inflammation-Associated diseases: recent advances and future directions. Molecules. 2020;25(22): 5342.
pubmed: 33207669
pmcid: 7696511
doi: 10.3390/molecules25225342
Fan Y, Chang Y, Wei L, Chen J, Li J, Goldsmith S, et al. Apoptosis of mural granulosa cells is increased in women with diminished ovarian reserve. J Assist Reprod Genet. 2019;36:1225–35.
pubmed: 30980221
pmcid: 6602993
doi: 10.1007/s10815-019-01446-5
Guan Y, Zhang W, Wang X, Cai P, Jia Q, Zhao W. Cell-free DNA induced apoptosis of granulosa cells by oxidative stress. Clin Chim Acta. 2017;473:213–7.
pubmed: 27884753
doi: 10.1016/j.cca.2016.11.023
Nagireddy S, Katneni L. Cell free DNA is an ideal ovarian reserve marker for low ovarian response for stimulation. Fertil Steril. 2019;112(3):e188.
doi: 10.1016/j.fertnstert.2019.07.607
Ebrahimi F, Rostami S, Nekoonam S, Rashidi Z, Sobhani A, Amidi F. The Effect of Astaxanthin and Metformin on oxidative stress in Granulosa cells of BALB C mouse model of polycystic ovary syndrome. Reprod Sci. 2021;28(10):2807–15.
pubmed: 33876387
doi: 10.1007/s43032-021-00577-4
Li Z, Dong X, Liu H, Chen X, Shi H, Fan Y, et al. Astaxanthin protects ARPE-19 cells from oxidative stress via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt. Mol vis. 2013;19:1656.
pubmed: 23901249
pmcid: 3725964